|
Age (years)
|
70.4 ± 8.0
|
72.0 ± 7.6
|
0.57
|
|
Gender (male/female)
|
15/2
|
9/6
|
0.08
|
|
Body mass index (kg/m2)
|
20.9 ± 2.6
|
23.4 ± 3.7
|
0.04
|
|
Diabetes mellitus (n, %)
|
11, 64.7 %
|
15, 100 %
|
0.01
|
|
Cardiovascular disease (n, %)
|
14, 82.4 %
|
14, 93.3 %
|
0.35
|
|
Cerebrovascular disease (n, %)
|
5, 29.4 %
|
5, 33.3 %
|
0.56
|
|
Duration of hemodialysis (years)
|
10.6 ± 9.1
|
9.9 ± 8.4
|
0.98
|
|
Laboratory data
| | | |
|
Total cholesterol (mg/dL)
|
161.2 ± 41.3
|
178.5 ± 46.3
|
0.24
|
|
Triglyceride (mg/dL)
|
98.1 ± 78.5
|
127.6 ± 48.0
|
0.03
|
|
High-density lipoprotein cholesterol (mg/dL)
|
52.1 ± 15.2
|
52.1 ± 14.0
|
0.99
|
|
C-reactive protein (mg/dL)
|
0.34 ± 0.63
|
0.44 ± 0.66
|
0.30
|
|
Albumin (g/dL)
|
3.51 ± 0.32
|
3.43 ± 0.28
|
0.46
|
|
Medications
| | | |
|
Statin (n, %)
|
4, 23.5 %
|
8, 53.3 %
|
0.08
|
|
Erythropoietin, darbepoetin alfa (n, %)
|
8, 47.1 %
|
7, 46.7 %
|
0.98
|
|
Erythropoietin, epoetin beta pegol (n, %)
|
5, 29.4 %
|
5, 33.3 %
|
0.81
|
|
Anti-platelet (n, %)
|
17, 100 %
|
15, 100 %
|
N/A
|
|
Warfarin (n, %)
|
2, 11.8 %
|
4, 26.7 %
|
0.27
|
|
Anti-hypertensive, ARB (n, %)
|
2, 11.8 %
|
1, 6.7 %
|
0.55
|
|
Anti-hypertensive, Ca antagonist (n, %)
|
4, 23.5 %
|
4, 26.7 %
|
0.58
|
|
Anti-hypertensive, Beta blocker (n, %)
|
3, 17.6 %
|
5, 33.3 %
|
0.27
|
|
Anti-hypertensive, Alpha blocker (n, %)
|
2, 11.8 %
|
0, 0 %
|
0.27
|
